Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma
Authors:
Open Access
- 12 February 2026
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Temozolomide (TMZ) resistance remains a major clinical obstacle in the treatment of glioblastoma (GBM), a highly aggressive brain tumor with poor prognosis. Growing evidence showed that metabolic reprogramming contributed to TMZ resistance and offered new avenues for intervention. This review comprehensively summarizes resistance-associated changes across three key areas – glycolysis, redox homeostasis, and lipid metabolism in TMZ-resistant GBM. The resistant cells tend to display enhanced glycolytic flux, with upregulation of glucose transporter and glycolysis enzymes. To counteract TMZ-induced oxidative stress, antioxidant systems are activated. Lipid metabolism is also extensively rewired, involving increased fatty acid oxidation, de novo lipogenesis, steroid hormone synthesis, and prostaglandin E₂-mediated signaling, along with a decreased ceramide level. Emerging preclinical research investigated therapeutic strategies targeting resistance-associated metabolic changes to reverse TMZ efficacy. Though preclinical research showed encouraging results, further validation in clinical settings is still needed. A deeper understanding of context-specific metabolic adaptations helps better elucidate the role of metabolism in resistance and to identify therapeutic opportunities with greater clinical translational potential.Keywords
Funding Information
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2021-I2M-1-014)
- non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (AY202410254)
- Peking Union Medical College Hospital Talent Cultivation Program (UBJ10254)
- Beijing Science and Technology Innovation Medical Development Foundation (AH1025400)
- Natural Science Foundation of Beijing Municipality (25L60061)
This publication has 120 references indexed in Scilit:
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated GlioblastomaJAMA Oncology, 2024
- Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron RetentionAdvanced Science, 2024
- Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathwaysNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- CN‐3 increases TMZ sensitivity and induces ROS‐dependent apoptosis and autophagy in TMZ‐resistance glioblastomaJournal of Biochemical and Molecular Toxicology, 2021
- Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II studyInvestigational New Drugs, 2020
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumorsInvestigational New Drugs, 2013
- Anticancer Agents That Counteract Tumor GlycolysisChemMedChem, 2012
- A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cellsCancer Chemotherapy and Pharmacology, 2009
- Ceramide levels are inversely associated with malignant progression of human glial tumorsGlia, 2002